# Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients

> **NCT06685653** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Nanjing Tianyinshan Hospital** · enrollment: 65 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **BIOLOGICAL:** Adebrelimab+RGL-270
- **BIOLOGICAL:** Adebrelimab+RGL-270/single RGL-270

## Key facts

- **NCT ID:** NCT06685653
- **Lead sponsor:** Nanjing Tianyinshan Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** —
- **Primary completion:** 2026-11-30
- **Final completion:** —
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06685653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06685653, "Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06685653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*